Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $0.46 in the prior trading day, BioAtla Inc (NASDAQ: BCAB) closed at $0.43, down -7.41%. In other words, the price has decreased by -$7.41 from its previous closing price. On the day, 0.68 million shares were traded.
Ratios:
Our goal is to gain a better understanding of BCAB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.35 and its Current Ratio is at 2.35. In the meantime, Its Debt-to-Equity ratio is 1.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On September 15, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $17.
Credit Suisse Downgraded its Outperform to Neutral on May 05, 2022, whereas the target price for the stock was revised from $35 to $5.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.27 while its Price-to-Book (P/B) ratio in mrq is 45.71.
Stock Price History:
Over the past 52 weeks, BCAB has reached a high of $2.53, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 4.85%, while the 200-Day Moving Average is calculated to be -56.63%.
Shares Statistics:
A total of 58.40M shares are outstanding, with a floating share count of 44.57M. Insiders hold about 23.70% of the company’s shares, while institutions hold 18.51% stake in the company.
